Exemestane

• Breast Cancer (Hormone Receptor-Positive)
• Adjuvant Breast Cancer Treatment
• Aromatase Inhibitor Therapy
• Estrogen Receptor-Positive Cancer

Exemestane (brand name Aromasin) is an oral steroidal aromatase inhibitor used in the adjuvant and metastatic treatment of hormone receptor-positive breast cancer in postmenopausal women. By irreversibly inactivating the aromatase enzyme, it lowers circulating estrogen to near-undetectable levels and starves estrogen-driven tumors of the hormonal signal they depend on for growth. Although typically initiated and monitored by oncology, primary care providers play a central role in managing the long-term toxicities — bone loss, joint pain, hot flashes, and cardiovascular risk — that accompany years of aromatase inhibitor therapy.

Mechanism of Action

Exemestane is an androstenedione analog that acts as a false substrate for aromatase. Once it binds the enzyme, it is partially metabolized into a reactive intermediate that forms a covalent bond with the active site, permanently inactivating it. Because the inhibition is irreversible, restoration of aromatase activity requires de novo enzyme synthesis — a process that takes days. This mechanism is sometimes called suicide inhibition.

In postmenopausal women, ovarian estrogen production has effectively ceased, and peripheral aromatization of adrenal androgens in fat, muscle, and breast tissue is the principal source of circulating estrogen. Exemestane suppresses serum estradiol by 85 to 95 percent in this setting. The non-steroidal aromatase inhibitors anastrozole and letrozole bind the same enzyme reversibly and are pharmacologically related but not chemically cross-reactive — meaning a patient who has progressed on one of these may still derive benefit from exemestane and vice versa, an important clinical consideration in second-line decision-making.

Clinical Use

For postmenopausal women with hormone receptor-positive early breast cancer, current ASCO and NCCN guidelines support five to ten years of adjuvant endocrine therapy. Exemestane is most commonly used as a switch agent after two to three years of tamoxifen — the IES trial demonstrated improved disease-free survival with this sequence — or as initial monotherapy in patients with contraindications to tamoxifen, such as a history of thromboembolism or endometrial pathology. Some patients tolerate exemestane better than non-steroidal aromatase inhibitors and switch among the three agents based on side-effect profile.

In the metastatic setting, exemestane is given alone, in combination with the mTOR inhibitor everolimus (the BOLERO-2 regimen for endocrine-resistant disease), or paired with a CDK4/6 inhibitor such as palbociclib, ribociclib, or abemaciclib. The choice between a steroidal (exemestane) and non-steroidal (anastrozole, letrozole) aromatase inhibitor at first line is largely driven by tolerability and cost; outcomes are broadly comparable. Patients with significant arthralgias on one agent occasionally do better on another, so trialing a switch before abandoning the class entirely is reasonable. Premenopausal women must undergo ovarian function suppression before any aromatase inhibitor can be considered, since unopposed gonadotropin feedback would otherwise stimulate ovarian estrogen output. The American Cancer Society overview of hormone therapy for breast cancer provides patient-level detail.

How to Take It

Exemestane is a 25 mg tablet taken once daily after a meal — food increases absorption by about 40 percent compared with the fasting state, and consistent administration with food improves predictability of exposure. The same time of day each day is preferred. If a dose is missed and the next dose is more than a few hours away, it can be taken with a snack; otherwise the missed dose is skipped, and doses are never doubled. Tablets are stored at room temperature in their original container.

Patients should be counseled to expect some hot flashes, joint stiffness (most pronounced in hands, knees, and feet), morning fatigue, and decreased libido, particularly in the first three months. The arthralgia is often worst on awakening and improves with movement; mild exercise, weight management, vitamin D repletion, and over-the-counter analgesics such as acetaminophen help most patients tolerate it. Some require dose-holds and rechallenge or a switch to a non-steroidal alternative. A reasonable practice is to introduce exemestane during a relatively low-stress period of life so any early adjustment is not confounded by other stressors.

Monitoring and Follow-Up

Before starting exemestane, postmenopausal status must be confirmed — by age, surgical history, or laboratory values (FSH, estradiol) where uncertain. Baseline DEXA scan, lipid panel, vitamin D level, and liver enzymes are obtained; the lipid panel and DEXA are repeated periodically because aromatase inhibitors accelerate bone loss and may modestly worsen lipids. The understanding blood work lab panels article explains many of the relevant tests, and bone health after 50 covers the rationale for skeletal surveillance during endocrine therapy.

Patients with osteopenia or osteoporosis at baseline often require concurrent bisphosphonate therapy with zoledronic acid, alendronate, or denosumab — there is good evidence that adjuvant zoledronic acid in postmenopausal women on aromatase inhibitors not only protects bone but may reduce breast cancer recurrence. Routine vitamin D and calcium intake should be optimized, and weight-bearing exercise encouraged. The FDA prescribing information is available through accessdata.fda.gov.

Special Populations

Exemestane is contraindicated in premenopausal and pregnant women — confirmation of menopause is essential, and premenopausal patients with hormone receptor-positive disease require ovarian suppression before any aromatase inhibitor can be used. Strong CYP3A4 inducers such as rifampin, phenytoin, carbamazepine, and St. John's wort substantially reduce exposure and may require dose escalation to 50 mg daily.

No dose adjustment is required for mild-to-moderate renal or hepatic impairment, although severe hepatic impairment data are limited and conservative monitoring is appropriate. Estrogen-containing products of any kind — including topical and vaginal estradiol preparations — defeat the purpose of the drug and should be avoided unless explicitly approved by the oncologist; for severe genitourinary symptoms, non-hormonal options or low-dose local estriol may be considered with oncologist input. Older adults tolerate the drug similarly to younger postmenopausal women, but baseline cardiovascular and bone risk is higher and monitoring should be correspondingly attentive.

Lifestyle and Supportive Care

Managing the side effects of long-term aromatase inhibitor therapy is largely about cumulative small interventions. For hot flashes, layering clothing, lowering bedroom temperatures, identifying and avoiding personal triggers (often spicy food, alcohol, and caffeine), and considering non-hormonal medications such as low-dose venlafaxine or gabapentin can substantially improve quality of life. Cognitive behavioral therapy and acupuncture have moderate evidence for both vasomotor symptoms and arthralgia.

For joint pain — the most common reason patients consider stopping aromatase inhibitors — regular moderate exercise paradoxically helps more than rest. Walking, swimming, yoga, and tai chi reduce stiffness and improve function. Vitamin D repletion to a serum 25-OH level above 30 ng/mL appears to reduce arthralgia in some patients. Weight loss in overweight or obese women lowers both joint pain and breast cancer recurrence risk; even modest losses translate to meaningful symptom relief.

Bone health requires attention to weight-bearing exercise, dietary calcium, vitamin D supplementation, and avoidance of smoking and excessive alcohol. Genitourinary symptoms — vaginal dryness, dyspareunia, urinary urgency — are common and often undertreated; non-hormonal moisturizers and lubricants are first-line, and selected patients with severe symptoms may use very low-dose vaginal estrogen with oncologist agreement after a careful risk discussion. Cardiovascular risk modification — blood pressure control, lipid management, healthy diet — becomes increasingly important during a years-long course of any endocrine therapy. Mental health support is appropriate for any patient struggling with the emotional weight of long-term cancer treatment.

When to Contact Your Doctor

Report any new bone pain, particularly persistent localized pain that does not respond to rest or activity modification, since this may signal a fracture or, rarely, disease progression in metastatic disease. Severe or progressive joint pain that is not relieved by simple measures should prompt reassessment. Signs of liver dysfunction (jaundice, dark urine, persistent right upper quadrant pain), unusual fatigue or shortness of breath, and any symptoms suggesting a blood clot — leg swelling, chest pain, sudden shortness of breath — warrant urgent evaluation. The MedlinePlus exemestane page summarizes warning signs in patient-friendly language.

If you have questions about exemestane or your breast cancer treatment plan, our team at Zimmer Medical Group can help — contact us or schedule a visit.